Raghad Alrashidi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Raghad Alrashidi has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Reema Almeshari
College of Pharmacy, Princess Nourah Bint Abdulrahman University, Riyadh 11564, Saudi Arabia
2 shared publications - Renad Alhaqbani
College of Pharmacy, Princess Nourah Bint Abdulrahman University, Riyadh 11564, Saudi Arabia
2 shared publications - Abdullah A. Alzahrani
Department of Pharmacy Practice, College of Pharmacy, King Saud Bin Abdulaziz University for Health Sciences (KSAU-HS) - Riyadh (Saudi Arabia), Saudi Arabia
1 shared publication - Abdulmohsen Alanazi
Clinical Pharmacy Department, King Fahad Medical City, Riyadh 12231, Saudi Arabia
1 shared publication - Ahlam Alghamdi
Department of Pharmacy Practice, College of Pharmacy, Princess Nourah bint Abdulrahman University, P.O. Box 84428, Riyadh 11671, Saudi Arabia
1 shared publication - Alwaleed Alharbi
Clinical Pharmacy Department, King Fahad Medical City, Riyadh 12231, Saudi Arabia
1 shared publication
Latest Publications
- Open Access
- 21 October 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (20) , 7428
Comparative Effectiveness of SGLT2i and GLP-1RA on Blood Pressure in Hypertensive Patients with Type 2 Diabetes: A Saudi Multicenter Retrospective Study
Background/Objectives: Sodium–glucose cotransporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) have shown blood pressure (BP) reduction in type 2 diabetes (T2D). However, head-to-head comparisons in hypertensive patients remain limited. This study assessed the effects of SGLT2i and GLP-1RA on systolic BP (SBP), diastolic BP (DBP), antihypertensive regimen modifications, and adverse events in Saudi patients with both conditions. Methods: A retrospective cohort study was conducted between January 2022 and April 2024 using records from two hospitals. Adults with T2D and hypertension who initiated SGLT2i or GLP-1RA and had ≥2 BP readings were included. BP changes were analyzed with ANOVA; adverse events and treatment discontinuation were assessed with Chi-square and Kaplan–Meier analysis. Results: Of 505 patients, 291 (57.6%) received SGLT2i and 214 received GLP-1RA. Both classes significantly reduced SBP (p < 0.001), and DBP decreased significantly only in the SGLT2i group (p < 0.001). Antihypertensive regimen reduction occurred in 6.9% of patients, most commonly among SGLT2i users (74.3%), while 76.8% remained on the same regimen; the remaining patients had other modifications such as dosage adjustments or changes in individual agents. Adverse events occurred in 6.3% of patients with no group differences. Therapy discontinuation was higher with GLP-1RA (12.6%) versus SGLT2i (2.4%, p < 0.001). Conclusions: Both SGLT2i and GLP-1RA might be considered in patients with T2D and hypertension, with SGLT2i potentially offering additional benefits for DBP reduction and simplifying antihypertensive regimens, which could support clinical decision-making in real-world practice.
- 21 October 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (20) , 7428
Open AccessComparative Effectiveness of SGLT2i and GLP-1RA on Blood Pressure in Hypertensive Patients with Type 2 Diabetes: A Saudi Multicenter Retrospective Study
Background/Objectives: Sodium–glucose cotransporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) have shown blood pressure (BP) reduction in type 2 diabetes (T2D). However, head-to-head comparisons in hypertensive patients remain limited. This study assessed the effects of SGLT2i and GLP-1RA on systolic BP (SBP), diastolic BP (DBP), antihypertensive regimen modifications, and adverse events in Saudi patients with both conditions. Methods: A retrospective cohort study was conducted between January 2022 and April 2024 using records from two hospitals. Adults with T2D and hypertension who initiated SGLT2i or GLP-1RA and had ≥2 BP readings were included. BP changes were analyzed with ANOVA; adverse events and treatment discontinuation were assessed with Chi-square and Kaplan–Meier analysis. Results: Of 505 patients, 291 (57.6%) received SGLT2i and 214 received GLP-1RA. Both classes significantly reduced SBP (p < 0.001), and DBP decreased significantly only in the SGLT2i group (p < 0.001). Antihypertensive regimen reduction occurred in 6.9% of patients, most commonly among SGLT2i users (74.3%), while 76.8% remained on the same regimen; the remaining patients had other modifications such as dosage adjustments or changes in individual agents. Adverse events occurred in 6.3% of patients with no group differences. Therapy discontinuation was higher with GLP-1RA (12.6%) versus SGLT2i (2.4%, p < 0.001). Conclusions: Both SGLT2i and GLP-1RA might be considered in patients with T2D and hypertension, with SGLT2i potentially offering additional benefits for DBP reduction and simplifying antihypertensive regimens, which could support clinical decision-making in real-world practice.
- Open Access
- 5 September 2025
- Published by MDPI AG in Preprints.org
Antitoxin, Supportive Care, and Adjunctive Therapies in Foodborne Botulism: A Comprehensive Systematic Review and Meta-Analysis
Background: Foodborne botulism is a rare but potentially fatal neuroparalytic illness caused by ingestion of Clostridium botulinum neurotoxins. Current treatment strategies include antitoxin administration, supportive care, and adjunctive therapies such as guanidine and 3,4-diaminopyridine. However, evidence comparing the efficacy of these interventions remain limited and inconclusive. This systematic review and meta-analysis aimed to evaluate treatment outcomes and compare the effectiveness of antitoxin, supportive care, and adjunctive therapies in managing foodborne botulism. Methods: A systematic search of PubMed and Web of Science was performed, and relevant studies were screened using predefined criteria. Data extraction and quality assessment were conducted independently by two reviewers. Pooled treatment success rates were calculated using random-effects meta-analysis with heterogeneity assessed via I² statistics. Results: 38 studies met our inclusion criteria, including case reports, case series, and observational studies. Pooled treatment success rates were high for antitoxin (95.3%, 95% CI: 91.3–97.8; pConclusions: Antitoxin remains standard care for foodborne botulism, though supportive care and adjunctive treatments also show favorable outcomes. Further multicenter studies with standardized protocols are needed to optimize management.
- 5 September 2025
- Published by MDPI AG in Preprints.org
Open AccessAntitoxin, Supportive Care, and Adjunctive Therapies in Foodborne Botulism: A Comprehensive Systematic Review and Meta-Analysis
Background: Foodborne botulism is a rare but potentially fatal neuroparalytic illness caused by ingestion of Clostridium botulinum neurotoxins. Current treatment strategies include antitoxin administration, supportive care, and adjunctive therapies such as guanidine and 3,4-diaminopyridine. However, evidence comparing the efficacy of these interventions remain limited and inconclusive. This systematic review and meta-analysis aimed to evaluate treatment outcomes and compare the effectiveness of antitoxin, supportive care, and adjunctive therapies in managing foodborne botulism. Methods: A systematic search of PubMed and Web of Science was performed, and relevant studies were screened using predefined criteria. Data extraction and quality assessment were conducted independently by two reviewers. Pooled treatment success rates were calculated using random-effects meta-analysis with heterogeneity assessed via I² statistics. Results: 38 studies met our inclusion criteria, including case reports, case series, and observational studies. Pooled treatment success rates were high for antitoxin (95.3%, 95% CI: 91.3–97.8; pConclusions: Antitoxin remains standard care for foodborne botulism, though supportive care and adjunctive treatments also show favorable outcomes. Further multicenter studies with standardized protocols are needed to optimize management.